GlobalSafetyDatabaseCompanySafetyCommitteeSafetyInformationIndividualCaseSafetyReportSideeffectNew DrugApplicationImportantPotentialRisksClinicalDevelopmentProgramDevelopmentalRiskManagementPlanInvestigationalNew DrugApplicationLiteratureReportBusinessPartnerAggregateSafetyReport(ASR)CompanyCoreSafetyInformationInvestigator’sBrochureDearInvestigatorLetterOtherSafetyIssueChiefSafetyOfficerProductHealthcareProfessionalSafetyAssessmentTeamWorld HealthOrganizationOff-labeluseMarketingAuthorizationHolderReferenceSafetyInformationSafetyDataExchangeAgreementPeriodicSafetyUpdateReportPeriodicBenefit-RiskEvaluationReportPharmacovigilanceperiodicsafetyupdatereport(PSUR)SignalManagementProcessInformedConsentCausalityAssessmentAffiliateInvestigatorDrugAbuseRiskManagementUrgentSafetyMeasureCouncil forInternationalOrganizationsof MedicalSciencesNon-InterventionalStudyRisk-BenefitBalanceSignalValidationAdverseEvent(AE)DrugProductAdverseEvent ofSpecialInterest(AESI)SpecialSituationsprocessexcellenceQualityAssuranceRiskCommunicationPharmacoepidemiologyNon-validatedsignalCountrySafetyLead/ManagerComparatorProductPharmacovigilanceGVPModuleIBeiGeneRepresentativeDevelopmentSafetyUpdateReportBlindingorMaskingGoodPharmacovigilancePracticeSeriousAdverseEventPost-authorizationSafety StudyExpectednessRegulatoryauthorityClinicalTrialPost-MarketingSurveillanceProductSafetyStrategySignalPrioritizationCompanyCore DataSheetPharmacovigilanceSystem MasterFileContractResearchOrganization(CRO)Spontaneous(Unsolicited)reportProductQualityComplaintSubjectMatterExpertSignalDetectionPlanAdverseEventReportNumberOverdoseSafetySignalQualified PersonforPharmacovigilanceHealthAuthorityInterventionalStudyDataLockPointRefutedSignalEudraVigilancePatientSafetyTolerabilityListedness/expectednessMonitoringPlanMedicalDictionary forRegulatoryActivities(MedRA)PharmacovigilanceSystemBusinessContinuityPlanMedicinesandHealthcareRegulatoryAgencyClinicalStudyObservationalstudySuspectedUnexpectedSeriousAdverseReaction(SUSAR)Benefit-riskanalysisIdentifiedRiskSponsorSignalDetectionLabeledorunlabeledGlobalPatientSafetyLocal SafetyRepresentativeInstitutionalReviewBoardNon-seriousAESIalliancemanagementProductRecallRiskManagementPlanInternationalConferenceonHarmonization(ICH)DevelopmentInternationalBirth DateCorrectiveandPreventiveAction(CAPA)backgroundratesInvestigationalMedicinalProductOccupationalexposureAdverseDrugReaction(ADR)ValidatedSignalUnexpectedEventsGoodClinicalPracticeIndividualCase SafetyReport(ICSR)OrganizedDataCollectionProgramNationalMedicalProductAdministrationDrugAdverseEventReportingSystemSolicitedreportsQualityManagementSystem(QMS)MedicalReviewSignalAssessmentPVAgreementClinicalTrialApplicationSafetyManagementTeamClinicalStudyNumberDrugSubstanceProtocolGlobalSafetyDatabaseCompanySafetyCommitteeSafetyInformationIndividualCaseSafetyReportSideeffectNew DrugApplicationImportantPotentialRisksClinicalDevelopmentProgramDevelopmentalRiskManagementPlanInvestigationalNew DrugApplicationLiteratureReportBusinessPartnerAggregateSafetyReport(ASR)CompanyCoreSafetyInformationInvestigator’sBrochureDearInvestigatorLetterOtherSafetyIssueChiefSafetyOfficerProductHealthcareProfessionalSafetyAssessmentTeamWorld HealthOrganizationOff-labeluseMarketingAuthorizationHolderReferenceSafetyInformationSafetyDataExchangeAgreementPeriodicSafetyUpdateReportPeriodicBenefit-RiskEvaluationReportPharmacovigilanceperiodicsafetyupdatereport(PSUR)SignalManagementProcessInformedConsentCausalityAssessmentAffiliateInvestigatorDrugAbuseRiskManagementUrgentSafetyMeasureCouncil forInternationalOrganizationsof MedicalSciencesNon-InterventionalStudyRisk-BenefitBalanceSignalValidationAdverseEvent(AE)DrugProductAdverseEvent ofSpecialInterest(AESI)SpecialSituationsprocessexcellenceQualityAssuranceRiskCommunicationPharmacoepidemiologyNon-validatedsignalCountrySafetyLead/ManagerComparatorProductPharmacovigilanceGVPModuleIBeiGeneRepresentativeDevelopmentSafetyUpdateReportBlindingorMaskingGoodPharmacovigilancePracticeSeriousAdverseEventPost-authorizationSafety StudyExpectednessRegulatoryauthorityClinicalTrialPost-MarketingSurveillanceProductSafetyStrategySignalPrioritizationCompanyCore DataSheetPharmacovigilanceSystem MasterFileContractResearchOrganization(CRO)Spontaneous(Unsolicited)reportProductQualityComplaintSubjectMatterExpertSignalDetectionPlanAdverseEventReportNumberOverdoseSafetySignalQualified PersonforPharmacovigilanceHealthAuthorityInterventionalStudyDataLockPointRefutedSignalEudraVigilancePatientSafetyTolerabilityListedness/expectednessMonitoringPlanMedicalDictionary forRegulatoryActivities(MedRA)PharmacovigilanceSystemBusinessContinuityPlanMedicinesandHealthcareRegulatoryAgencyClinicalStudyObservationalstudySuspectedUnexpectedSeriousAdverseReaction(SUSAR)Benefit-riskanalysisIdentifiedRiskSponsorSignalDetectionLabeledorunlabeledGlobalPatientSafetyLocal SafetyRepresentativeInstitutionalReviewBoardNon-seriousAESIalliancemanagementProductRecallRiskManagementPlanInternationalConferenceonHarmonization(ICH)DevelopmentInternationalBirth DateCorrectiveandPreventiveAction(CAPA)backgroundratesInvestigationalMedicinalProductOccupationalexposureAdverseDrugReaction(ADR)ValidatedSignalUnexpectedEventsGoodClinicalPracticeIndividualCase SafetyReport(ICSR)OrganizedDataCollectionProgramNationalMedicalProductAdministrationDrugAdverseEventReportingSystemSolicitedreportsQualityManagementSystem(QMS)MedicalReviewSignalAssessmentPVAgreementClinicalTrialApplicationSafetyManagementTeamClinicalStudyNumberDrugSubstanceProtocol

Untitled Bingo - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
  1. Global Safety Database
  2. Company Safety Committee
  3. Safety Information
  4. Individual Case Safety Report
  5. Side effect
  6. New Drug Application
  7. Important Potential Risks
  8. Clinical Development Program
  9. Developmental Risk Management Plan
  10. Investigational New Drug Application
  11. Literature Report
  12. Business Partner
  13. Aggregate Safety Report (ASR)
  14. Company Core Safety Information
  15. Investigator’s Brochure
  16. Dear Investigator Letter
  17. Other Safety Issue
  18. Chief Safety Officer
  19. Product
  20. Healthcare Professional
  21. Safety Assessment Team
  22. World Health Organization
  23. Off-label use
  24. Marketing Authorization Holder
  25. Reference Safety Information
  26. Safety Data Exchange Agreement
  27. Periodic Safety Update Report
  28. Periodic Benefit-Risk Evaluation Report
  29. Pharmacovigilance
  30. periodic safety update report (PSUR)
  31. Signal Management Process
  32. Informed Consent
  33. Causality Assessment
  34. Affiliate
  35. Investigator
  36. Drug Abuse
  37. Risk Management
  38. Urgent Safety Measure
  39. Council for International Organizations of Medical Sciences
  40. Non-Interventional Study
  41. Risk-Benefit Balance
  42. Signal Validation
  43. Adverse Event (AE)
  44. Drug Product
  45. Adverse Event of Special Interest (AESI)
  46. Special Situations
  47. process excellence
  48. Quality Assurance
  49. Risk Communication
  50. Pharmacoepidemiology
  51. Non-validated signal
  52. Country Safety Lead/Manager
  53. Comparator Product
  54. Pharmacovigilance
  55. GVP Module I
  56. BeiGene Representative
  57. Development Safety Update Report
  58. Blinding or Masking
  59. Good Pharmacovigilance Practice
  60. Serious Adverse Event
  61. Post-authorization Safety Study
  62. Expectedness
  63. Regulatory authority
  64. Clinical Trial
  65. Post-Marketing Surveillance
  66. Product Safety Strategy
  67. Signal Prioritization
  68. Company Core Data Sheet
  69. Pharmacovigilance System Master File
  70. Contract Research Organization (CRO)
  71. Spontaneous (Unsolicited) report
  72. Product Quality Complaint
  73. Subject Matter Expert
  74. Signal Detection Plan
  75. Adverse Event Report Number
  76. Overdose
  77. Safety Signal
  78. Qualified Person for Pharmacovigilance
  79. Health Authority
  80. Interventional Study
  81. Data Lock Point
  82. Refuted Signal
  83. EudraVigilance
  84. Patient Safety
  85. Tolerability
  86. Listedness/ expectedness
  87. Monitoring Plan
  88. Medical Dictionary for Regulatory Activities (MedRA)
  89. Pharmacovigilance System
  90. Business Continuity Plan
  91. Medicines and Healthcare Regulatory Agency
  92. Clinical Study
  93. Observational study
  94. Suspected Unexpected Serious Adverse Reaction (SUSAR)
  95. Benefit-risk analysis
  96. Identified Risk
  97. Sponsor
  98. Signal Detection
  99. Labeled or unlabeled
  100. Global Patient Safety
  101. Local Safety Representative
  102. Institutional Review Board
  103. Non-serious AESI
  104. alliance management
  105. Product Recall
  106. Risk Management Plan
  107. International Conference on Harmonization (ICH)
  108. Development International Birth Date
  109. Corrective and Preventive Action (CAPA)
  110. background rates
  111. Investigational Medicinal Product
  112. Occupational exposure
  113. Adverse Drug Reaction (ADR)
  114. Validated Signal
  115. Unexpected Events
  116. Good Clinical Practice
  117. Individual Case Safety Report (ICSR)
  118. Organized Data Collection Program
  119. National Medical Product Administration
  120. Drug Adverse Event Reporting System
  121. Solicited reports
  122. Quality Management System (QMS)
  123. Medical Review
  124. Signal Assessment
  125. PV Agreement
  126. Clinical Trial Application
  127. Safety Management Team
  128. Clinical Study Number
  129. Drug Substance
  130. Protocol